Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
43,692,643
-
Total 13F shares
-
31,935,411
-
Share change
-
+1,243,689
-
Total reported value
-
$239,516,646
-
Put/Call ratio
-
231%
-
Price per share
-
$7.50
-
Number of holders
-
87
-
Value change
-
-$86,044,405
-
Number of buys
-
60
-
Number of sells
-
41
Institutional Holders of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) as of Q2 2024
As of 30 Jun 2024 Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) had 87 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 31,935,411 shares of stock of the company.
Largest 10 holders included Vida Ventures Advisors, LLC, Bain Capital Life Sciences Investors, LLC, Northpond Ventures, LLC, JPMORGAN CHASE & CO, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), RTW INVESTMENTS, LP, Novo Holdings A/S, BlackRock Inc., VANGUARD GROUP INC, and MILLENNIUM MANAGEMENT LLC.
This table shows 87 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.